Press Release
Latest Clinical Data of InnoCare’s Gunagratinib Presented at 2023 ASCO GI
26 Jan, 2023
75
4060
InnoCare to Present Latest Clinical Data of Gunagratinib at the Upcoming 2023 ASCO GI
05 Jan, 2023
100
4050
InnoCare Announces Approval of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong
28 Dec, 2022
121
4048
InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Orelabrutinib in Combination with Tafasitamab + Lenalidomide in China
21 Dec, 2022
69
4045
InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Mantle Cell Lymphoma in Singapore
22 Nov, 2022
107
4042
InnoCare Releases 2022 Third Quarter Results: Star Board Listing for Long-term Growth and Rapid Increase of Orelabrutinib Sales
14 Nov, 2022
170
4033
10 Studies on Orelabrutinib Selected at the Upcoming 64th Annual Meeting of ASH
08 Nov, 2022
89
4030
InnoCare Announces First Adolescent Patient Dosed in Clinical Trial of pan-TRK Inhibitor ICP-723 in China
31 Oct, 2022
87
4021
InnoCare Completes Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
21 Sep, 2022
143
3982
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in China
13 Sep, 2022
98
3948